AR124841A1 - Compuestos antibacterianos - Google Patents

Compuestos antibacterianos

Info

Publication number
AR124841A1
AR124841A1 ARP220100257A ARP220100257A AR124841A1 AR 124841 A1 AR124841 A1 AR 124841A1 AR P220100257 A ARP220100257 A AR P220100257A AR P220100257 A ARP220100257 A AR P220100257A AR 124841 A1 AR124841 A1 AR 124841A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
membered heterocycloalkyl
cycloalkyl
unsubstituted
Prior art date
Application number
ARP220100257A
Other languages
English (en)
Spanish (es)
Inventor
Min Teng
Baskar Nammalwar
Xiaoming Li
Christian Perez
David T Puerta
Original Assignee
Forge Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forge Therapeutics Inc filed Critical Forge Therapeutics Inc
Publication of AR124841A1 publication Critical patent/AR124841A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
ARP220100257A 2021-02-11 2022-02-08 Compuestos antibacterianos AR124841A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163148261P 2021-02-11 2021-02-11

Publications (1)

Publication Number Publication Date
AR124841A1 true AR124841A1 (es) 2023-05-10

Family

ID=82837229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100257A AR124841A1 (es) 2021-02-11 2022-02-08 Compuestos antibacterianos

Country Status (7)

Country Link
US (1) US20240166609A1 (https=)
EP (1) EP4291550A4 (https=)
JP (1) JP2024507139A (https=)
CN (1) CN117279897A (https=)
AR (1) AR124841A1 (https=)
TW (1) TW202246218A (https=)
WO (1) WO2022173758A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019345150A1 (en) * 2018-09-20 2021-05-13 Blacksmith Medicines, Inc. Antibacterial compounds
TW202322818A (zh) 2021-09-28 2023-06-16 美商福吉醫療公司 Lpxc抑制劑及其用途
TW202417432A (zh) * 2022-08-10 2024-05-01 美商布萊克史密斯醫藥公司 抗菌化合物
WO2025174875A1 (en) * 2024-02-13 2025-08-21 Blacksmith Medicines, Inc. Antibacterial compounds
WO2025174868A1 (en) * 2024-02-13 2025-08-21 Blacksmith Medicines, Inc. Antibacterial compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3180749B2 (ja) 1997-12-26 2001-06-25 ダイソー株式会社 3−ヒドロキシ−γ−ブチロラクトン誘導体の新規製法
WO2008027466A1 (en) * 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
JP6006609B2 (ja) * 2011-10-19 2016-10-12 大正製薬株式会社 新規なヒドロキサム酸誘導体を含有する医薬
WO2015085238A1 (en) * 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
DK3233843T3 (da) * 2014-12-16 2019-11-18 Novartis Ag Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
WO2018208987A2 (en) * 2017-05-10 2018-11-15 Forge Therapeutics, Inc. Antibacterial compounds
WO2018216822A1 (en) 2017-05-25 2018-11-29 Taisho Pharmaceutical Co., Ltd. Novel imidazole derivatives
WO2020102572A1 (en) 2018-11-14 2020-05-22 Forge Therapeutics, Inc. Antibacterial compounds
KR20210093884A (ko) * 2018-11-21 2021-07-28 다이쇼 세이야꾸 가부시끼가이샤 신규 이미다졸 유도체
AR124839A1 (es) * 2021-02-11 2023-05-10 Forge Therapeutics Inc Compuestos antibacterianos

Also Published As

Publication number Publication date
JP2024507139A (ja) 2024-02-16
WO2022173758A1 (en) 2022-08-18
CN117279897A (zh) 2023-12-22
EP4291550A1 (en) 2023-12-20
US20240166609A1 (en) 2024-05-23
EP4291550A4 (en) 2025-01-22
TW202246218A (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
AR124841A1 (es) Compuestos antibacterianos
AR124839A1 (es) Compuestos antibacterianos
AR086095A1 (es) Derivados de nucleosidos 2’-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR105643A1 (es) COMPUESTOS ANTIVIRALES DE FOSFODIAMIDA DE ÉSTER DE b-AMINOÁCIDO
AR096332A1 (es) Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR119010A1 (es) Compuestos, composiciones y métodos de uso
AR108906A1 (es) Heterociclos de biarilmetilo
AR086096A1 (es) Derivados de nucleosidos 2’-ciano sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR042956A1 (es) Inhibidores de girasa y usos de los mismos
AR106945A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR090590A1 (es) COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA
AR109437A1 (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
AR087757A1 (es) Inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7, sus composiciones farmaceuticas y sus aplicaciones terapeuticas
AR092307A1 (es) Derivados de manosa para el tratamiento de infecciones bacterianas
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
AR092959A1 (es) Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
UA110259C2 (uk) Похідні піролопіримідину і пурину
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
HRP20160623T1 (hr) Inhibitori proteinske kinaze
CY1114081T1 (el) Σπειροοξετανικα νουκλεοσιδια ουρακιλης ονες
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas

Legal Events

Date Code Title Description
FB Suspension of granting procedure